Stuy in NEJM: New therapy prevents hea...(al pumping action of the heart. Moss als...),Health

Date:9/1/2009

al pumping action of the heart. Moss, also principal investigator of the current MADIT-CRT trial, and his team designed MADIT-CRT as follow-up to MADIT-II. The new trial sought to determine if preventive CRT-D therapy, the combination of an ICD with CRT, could reduce the risk of mortality and heart failure in patients with mild cardiac disease and few symptoms (NYHA class I or II).

Over a 4 year period, 1820 patients from 110 medical centers in the United States, Canada, and Europe were enrolled and followed in MADIT-CRT. The trial was sponsored by Boston Scientific Corp. through a research grant to the University of Rochester. It is the world's largest randomized study involving NYHA class I and II patients. About 70 percent of the approximately 5.5 million Americans with some form of heart disease, or 3.9 million people, fall into NYHA class I or II.

"The findings from MADIT-CRT show that CRT-D effectively reduces the risk of heart failure," Moss said. "There is a very large population of patients with heart disease whom we believe will benefit from CRT-D therapy."

Prior to 2009, Moss received honoraria from Boston Scientific for talks at scientific programs. He holds no stock in any device company, has never been a member of any corporate speakers' bureau, and since Dec. 1, 2008, has chosen not to accept honoraria from Boston Scientific for any professional activity.

"This is a very important trial," said Richard Page, M.D., president of the Heart Rhythm Society. "Previous studies have shown that the ICD saves lives. This trial demonstrates that in this population, an ICD with biventricular pacing can be expected also to improve clinical outcome as measured by hospitalization for heart failure. I anticipate that these results may improve acceptance of ICD therapy, both by patients and their physicians, in that the patient would not only live longer, but also would live better."

'/>"/>

Contact: Greg Williams Greg_Williams@urmc.rochester.edu 585-273-1757 University of Rochester Medical Center Source:Eurekalert

1 GOOD

Page: 1 2
Related medicine news :

1. NEJM: Low-fat diets not best for weight loss: New study by Ben-Gurion U. of the Negev
2. Promise of nanodiamonds for safer gene therapy
3. Chemotherapy Linked to Sleep-Wake Cycle Disruptions
4. U.S. Compression Therapy Market to Reach $1.16 Billion in 2015, Finds Frost & Sullivan
5. The benefits of reperfusion therapy
6. Chemotherapy for breast cancer is associated with disruption of sleep-wake rhythm in women
7. CPF Submits Comments to CMS to Save Only Effective Therapy Available to PF Patients
8. Secca(R) Therapy - An Effective and Minimally Invasive Option for Treating Bowel Incontinence - Launched in the US
9. Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics
10. Researchers find high-dose therapy for liver disease not effective
11. NIH grant advances Tay-Sachs disease gene therapy